Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (Nasdaq:BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that Thomas Butler, Biomea Fusion’s Chief Executive Officer and Chairman of the Board, will present recent clinical progress and 2024 corporate milestones at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 from 8:15 am – 8:55 am PST.
Related news for (BMEA)
- 24/7 Market News Snapshot 06 October, 2025 – Biomea Fusion, Inc. Common Stock (NASDAQ:BMEA)
- Biomea Fusion Announces Proposed Public Offering of Securities
- Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
- 24/7 Market News Snapshot 06 October, 2025 – Biomea Fusion, Inc. Common Stock (NASDAQ:BMEA)
- MoBot’s Stock Market Highlights – 10/06/25 01:00 PM
